Home > Waters & Kraus, LLP > Legal Library

Legal Articles: Waters & Kraus, LLP

 







Document(s) published by this organization: 28


View Page: 1  2  3  Next  
Show: results per page
Sort by:

HTMLCRS-207 Receives Orphan Drug Status for Mesothelioma
Michael B. Gurien, Michael B. Gurien, Gary M. Paul, Gary M. Paul; Waters, Kraus & Paul;
Legal Alert/Article
April 22, 2015, previously published on April 6, 2015
CRS-207 has been granted orphan drug status by the U. S. Food and Drug Administration (FDA) for treatment of pleural mesothelioma patients. CRS-207, manufactured by Aduro Biotech, had previously been granted orphan drug designation for treatment of pancreatic cancer. The orphan drug designation is...

 

HTMLPower Morcellation May Spread Benign Disease as Well as Cancer
Kyla Gail Cole; Waters & Kraus, LLP;
Legal Alert/Article
April 22, 2015, previously published on April 8, 2015
Power morcellation, according to three Johns Hopkins physicians, can cause benign uterine disease to spread. Three case reports from the Baltimore Maryland hospital demonstrated that use of the morcellator medical device may require more extensive surgery later and increase a patient’s risk...

 

HTMLMetal-on-Metal Hip Implants Pose Potential Risk for Patients
Sara E. Coopwood; Waters & Kraus, LLP;
Legal Alert/Article
April 22, 2015, previously published on March 25, 2015
Metal-on-metal hip implants can lead to metal debris migrating from the device into the blood and surrounding tissue, according to the European Commission’s (EC’s) Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR). The EC described the potential health risk in...

 

HTMLXarelto Lawsuit Filed in West Virginia Against Drug’s Makers
Waters Kraus LLP;
Legal Alert/Article
April 22, 2015, previously published on April 10, 2015
A West Virginia man is suing Janssen Research & Development and Bayer Corporation, along with several of their affiliates, for misrepresenting the risks associated with Xarelto. Jermaine Tavon McMillan’s lawsuit was filed in federal court in West Virginia in February.

 

HTMLHigh Rates of Mesothelioma Found in Southern Nevada Residents
Michael B. Gurien, Gary M. Paul; Waters, Kraus & Paul;
Legal Alert/Article
April 22, 2015, previously published on March 23, 2015
Construction of Nevada highways has been delayed because of the discovery of high levels of asbestos in the soil. Scientists are concerned that the asbestos could be dangerous to residents living nearby. Asbestos exposure is the only confirmed cause of mesothelioma, an incurable cancer of the...

 

HTMLMesothelioma Patients May Benefit From Lymphoma Drug
Peter A. Kraus, Troyce G. Wolf; Waters & Kraus, LLP;
Legal Alert/Article
April 22, 2015, previously published on March 30, 2015
Mesothelioma patients whose disease is of the epithelioid subtype may benefit from treatment with a drug that is already being used in patients with large cell lymphoma and Hodgkin’s disease. Adcetris — or brentuximab vedotin — has been shown in encouraging new research to slow...

 

HTMLRemoval of Transvaginal Mesh May Not Fix Problems
Kyla Gail Cole; Waters & Kraus, LLP;
Legal Alert/Article
April 22, 2015, previously published on April 1, 2015
The dangers of vaginal mesh were recently addressed by the American College of Obstetricians and Gynecologists in an article that reviews data made available in the last year. Authored by John R. Fischer, M.D. of the Department of Obstetrics and Gynecology at the Uniformed Services University of...

 

HTMLUnitedHealth Restricts Coverage for Hysterectomies Involving Power Morcellator
Kyla Gail Cole; Waters & Kraus, LLP;
Legal Alert/Article
April 22, 2015, previously published on March 27, 2015
UnitedHealth Group Inc. is putting more restrictive coverage rules into place for hysterectomies performed with a power morcellator. The nation’s largest health insurer will reportedly require health care providers to provide advance notification and obtain advance approval for abdominal...

 

HTMLVerastem Mesothelioma Treatment Receives FDA’s Orphan Drug Designation
Waters Kraus LLP;
Legal Alert/Article
April 7, 2015, previously published on March 18, 2015
Verastem, Inc., a company that works to develop drugs to treat mesothelioma and other cancers by killing cancer stem cells, has announced that the U.S. Food and Drug Administration has granted Verastem’s VS-5584 an orphan drug designation. VS-5584 may prove to be effective for treating...

 

HTMLJ&J and Bayer Launch New Xarelto Study
Waters Kraus LLP;
Legal Alert/Article
April 7, 2015, previously published on March 20, 2015
Johnson & Johnson and Bayer are reportedly seeking additional Food and Drug Administration (FDA) approval for Xarelto, the companies’ lucrative blood thinner that many lawsuits claim can cause injuries and death from uncontrollable bleeding.

 


View Page: 1  2  3  Next